Molecular mechanism of monamine toxicity in Parkinson's disease: Hypothetical cell death model

Medical Hypotheses

Volumn 54, Issue 2, 2000, Pages 269-274

  Jimenez Del Rio, M ^a   Velez Pardo, C ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; METAL ION; MONOAMINE; BIOGENIC AMINE; METAL;

CELL DEATH; HUMAN; MODEL; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGICAL MODEL; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BIOGENIC MONOAMINES; CELL DEATH; DOPAMINE; HUMANS; METALS; MODELS, NEUROLOGICAL; NEURONS; PARKINSON DISEASE;

EID: 0033625739     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0839     Document Type: Article

References (79)

1. Zhang Z.-X., Roman G. C. Worldwide occurrence of parkinson's disease: an updated review. Neuroepidemiology. 12:1993;195-208.
2. Parkinson J. An assay on the shaking palsy. London (1817) Reproduced. Critchley M. James Parkinson. 1955;Macmillan, London.
3. Forno L. Neuropathology of Parkinson's disease. J Neuropath Exp Neurol. 55:1996;259-272.
4. Pollanem M. S., Dickson D. W., Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol. 52:1993;183-189.
5. Dwork A. I., Balmaceda A., Fazzini E. A. Dominantly inhereted early onset parkinsonism: neuropathology of a new form. Neurology. 43:1993;69-74.
6. Takahashi H., Ohama M. D., Suzuki S. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology. 44:1994;437-441.
7. Plante-Bordeneuve V., Taussing D., Thomas F. A clinical and genetic study of familial cases of Parkinson's disease. J Neurol Sci. 133:1995;164-172.
8. Mann V. M., Cooper J. M., Schapira A. H. V. Quantitation of a mithocondrial deletion in parkinson's disease. Fed Eur Biochem Soc. 299:1992;218-222.
9. Nakagawa-Hattori Y., Yoshino H., Kondo T. Is Parkinson's disease a mitochondrial disorder? J Neurol Sci. 107:1992;29-33.
10. Seidler A., Hellenbrand W., Robra B. P. Possible environmental, occupational and other etiologic factors for parkinson's disease: a case-control study in Germany. Neurology. 46:1996;1275-1284.
11. Olanow C., Arendash G. Metals and free radicals in neurodegeneration. Curr Opin Neurol. 7:1994;548-558.
12. Kopin I. J. Catecholamine metabolism: Basic aspects and clinical significance. Pharm Rev. 37:1985;333-386.
13. Fanh S., Cohen G. The oxidant stress Hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol. 32:1992;804-812.
14. Jenner P. What process causes nigral cell death in Parkinson's disease? Neurol Clin. 10:1992;387-403.
15. Ebadi M., Srinivasan S. K., Baxi M. Oxidative stress and antioxidant therapy in parkinson's disease. Prog Neurol. 48:1996;1-19.
16. Jenner P. Oxidative mechanism in nigral cell death in Parkinson's disease. Mov Disord. 13:1998;24-34.
17. Halliwell B., Gutteridge J. M. C. Oxygen is poisonous-an introduction to oxygen toxicity and free radicals. Halliwell B., Gutteridge J. M. C. Free Radicals in Biology and Medicine. 1989;1-20 Clarendon Press, Oxford.
18. Jenner P., Olanow C. W. Oxidative stress and the pathogenesis of parkinson's disease. Neurology. 47:1996;S161-S170.
19. Cohen, G. Faroqui, R. Kesler, N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow.
20. Graham D. G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol. 14:1978;633-643.
21. Brunmark A., Cadenas E. Redox and addition chemistry of quinoid compounds and its implications. Free Rad Biol Med. 7:1989;435-477.
22. Jellinger K. A., Kienzl E., Rumpelmaier G. Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol. 60:1993;267-272.
23. Kienzl E., Puchinger L., Jellinger K. The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci. 134:1995;69-78.
24. Hirsh E. C., Faucheux B. A. Iron metabolism and Parkinson's disease. Mov Disord. 13:1998;39-45.
25. Jellinger K., Kienzl E., Rumpelmaier G. Iron-melanin complex in substantia nigra of Parkinsonian brain: an X-ray microanalysis. J Neurochem. 59:1992;1168-1171.
26. Winterbourn C. C. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol Lett. 82/83:1995;969-974.
27. Halliwell B., Guterridge J. M. C. Role of free radicals and catalytic metal ions in human disease-an overview. Meth Enzymol. 186:1990;1-85.
28. Velez Pardo C., Jimenez Del Rio M., Verschueren H., Ebinger G., Vauquelin G. Dopamine and iron induce apoptosis in PC12 cells. Pharmacol Toxicol. 80:1997;76-84.
29. Tanaka M., Sotomatsu A., Kanai H., Hirai S. Dopa and dopamine cause cultured neuronal death in presence of iron. J Neurol Sci. 101:1991;198-203.
30. Dexter D. T., Carayon A., Javoy-Agid F. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative disease affecting the basal ganglia. Brain. 114:1991;1953-1975.
31. Gorell J. M., Johnson C. C., Rybicki B. A. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology. 48:1997;650-658.
32. Archibald F. S., Tyree C. Manganese poisoning and the attack of trivalent manganese upon catecholamines. Arch Biochem Biophys. 256:1987;638-650.
33. Montine T. J., Farris D. B., Graham D. G. Covalent crosslinking of neurofilament protein by oxidized catechols as a potential mechanism of Lewy body formation. J Neuropathol Exp Neurol. 54:1995;311-319.
34. Velez Pardo C., Jimenez Del Rio M., Ebinger G., Vauquelin G. Manganese and copper promote the binding of dopamine to 'serotonin binding proteins' in bovine frontal cortex. Neurochem Int. 26:1995;615-622.
35. Cohen G., Werner P. Free radicals, oxidative stress, and neurodegeneration. Calne D. B. Neurodegenerative Diseases. 1994;139-162 W.B., Saunders, Philadelphia.
36. Jellinger K., Linert L., Kienzl E. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm. 46:1997;297-314.
37. Pezzella A., D'ischia M., Napolitano A., Misuraca G., Prota G. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in parkinson's disease. J Med Chem. 40:1997;2211-2216.
38. Bruchelt G., Schraufsetatter I. U., Niethammer D., Cochrane C. G. Ascorbic acid enhances the effect of 6-hydroxydopamine and H2O2 on iron dependent DNA strand breaks and related processes in the neuroblastoma cell line SK-N-SH. Cancer Res. 51:1991;6066-6072.
39. Bindoli A., Rogobello M. P., Deeble D. J. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Rad Biol Med. 13:1992;391-405.
40. Husain S., Hadi S. M. Strand scission in DNA induced by L-DOPA in the presence of Cu(II). FEBS Lett. 364:1995;75-78.
41. Schwartzman R. A., Cidlowski J. A. Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocrine Rev. 14:1993;133-151.
42. Steller H. Mechanisms of genes and cellular suicide. Science. 267:1995;1445-1449.
43. Oppenheim R. W. Cell death during development of the nervous system. Annu Rev Neurosci. 14:1991;453-501.
44. Burke R. E. Programmed cell death and Parkinson's disease. Mov Disord. 13:1998;17-23.
45. Walker P. R., Kokileva LeBlanc L., Sikorska J. Detection of the initial stages of DNA fragmentation in apoptosis. Bio Techniques. 15:1993;1032-1036.
46. Tompkins M. M., Basgeall E. J., Zamrini E., Hill W. D. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol. 150:1997;119-131.
47. Michel P. P., Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res. 26:1990;428-435.
48. Ben-Shachar D., Youdim M. B. H. Intranigral iron injection induces behavioral and biochemical 'Parkinsonism' in rats. J Neurochem. 57:1991;2133-2135.
49. Sengstock G. J., Olanow C. W., Dunn A. J., Arendash G. W. Iron induced neurodegeneration of nigrostriatal neurons. Brain Res Bullet. 28:1992;645-649.
50. Mytilineou C., Han S. H., Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem. 61:1993;1470-1478.
51. Glinka Y., Tipton K. F., Youdim M. B. H. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem. 66:1996;2004-2010.
52. Tsao C.-W., Cheng J.-T., Shen C.-L., Lin Y.-S. 6-hydroxydopamine induces thymocyte apoptosis in mice. J Neuroimm. 65:1996;91-95.
53. Green L. A., Tischler A. S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci. 73:1976;2424-2428.
54. Velez Pardo C., Jimenez Del Rio M., Ebinger G., Vauquelin G. Monoamine and iron-related toxicity: from 'serotonin binding proteins' to lipid peroxidation and apoptosis in PC12 cells. Gen Pharmacol. 31:1998;19-24.
55. Langston J. W., Irwin I., Ricaurte G. A. Neurotoxins, Parkinsonism and Parkinson's disease. Pharmacol Ther. 32:1987;19-49.
56. Halliwell B., Aruoma O. I. DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett. 281:1991;9-19.
57. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 59:1992;1609-1623.
58. Walkinshaw G., Waters C. M. Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neurosci. 63:1994;975-987.
59. Walkinshaw G., Waters C. M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implication for the treatment of Parkinson's disease. J Clin Inv. 95:1995;2458-2464.
60. Zilkhafalb R., Ziv I., Nardi N., Offen D., Melamed E., Barzilai A. Monoamine-induced apoptotic neuronal cell death. Cell Mol Neurobiol. 17:1997;101-118.
61. Luo Y., Umegaki H., Wang X., Abe R., Roth G. S. Dopamnie induces apoptosis through an oxidation-involved SAPk/ JNK activation pathway. J Biol Chem. 273:1998;3756-3764.
62. Blum D., Wu Y., Nissou M.-F., Arnaud S., Benabid A. L., Verna J. M. p53 and Bax activation in 6-hydroxydopamine-induce apoptosis in PC12 cells. Brain Res. 751:1997;139-142.
63. Vauquelin G., Jimenez Del Rio M., Velez Pardo C. Serotonin binding proteins: an In vitro Model System fro monoamine-related neurotoxicity. Ann NY Acad Sci. 738:1994;409-418.
64. Jimenez Del Rio M., Velez Pardo C., Ebinger G., Vauquelin G. Serotonin binding proteins 'SBP': Target proteins and tool for in vitro neurotoxicity studies. Gen Pharmacol. 26:1995;1633-1641.
65. Jimenez Del Rio M., Velez Pardo C., Pinxteren J., De Potter W., Ebinger G., Vauquelin G. Binding of serotonin and dopamine to 'serotonin binding proteins' in bovine frontal cortex: evidence for iron-induced oxidative mechanisms. Eur J Pharmacol. 247:1993;11-21.
66. Velez Pardo C., Jimenez Del Rio M., Pinxteren J., De Potter W., Ebinger G., Vauquelin G. Fe2+-mediated binding of serotonin and dopamine to skeletal muscle actin: resemblance to serotonin binding proteins. Eur J Pharmacol. 288:1995;209-218.
67. Jimenez Del Rio M., Velez Pardo C., Pinxteren J., De Potter W., Ebinger G., Vauquelin G. Interaction of serotonin- and dopamine-related neurotoxins with 'serotonin binding proteins' in bovine frontal cortex. Biochem Pharmacol. 48:1994;253-258.
68. Velez-Pardo C., Jimenez Del Rio M., Ebinger G., Vauquelin G. Redox cycling activity of monoamine - 'serotonin binding protein' conjugates. Biochem Pharmacol. 51:1996;1521-1525.
69. Lander H. M., Ogiste J. S., Teng K. K., Novogrodsky A. p21-ras as a common singnaling target of reactive free radicals and celular redox stress. J Biol Chem. 270:1995;21195-21198.
70. Coso O. A., Chiariello M., Yu J.-C. The small GTP-binding proteins Racl and Cdc42 regulate the activity of the JNK/SAPK signalling pathway. Cell. 81:1995;1137-1146.
71. Schulzeosthoff K., Ferrari D., Riehemann K., Wesselbourg S. Regulation of NF-kappa -B activation by MAP Kinases cascades. Immunobiology. 198:1997;35-49.
72. Wu H., Lozano G. NF-kB activation of p53. J Biol Chem. 269:1994;20067-20074.
73. Miyashita T., Reed J. C. Tumor suppressor p53 is a direct transcriprtional activator of human bax gene. Cell. 80:1995;293-299.
74. Hunot S., Brugg B., Ricard D. Nuclear translocation of NF-κB is increased in dopaminergic neurons of pacients with Parkinson disease. Proc Natl Acad Sci. 94:1997;7531-7536.
75. Reed J. C. Cytochrome c: Can't live with it can't live without it. Cell. 91:1997;559-562.
76. Magyar K., Szende B., Lengyel J., Tekes K. The pharmacology of B-type selective monoamine oxidase inhibitors; milestone in (-)-deprenyl research. J Neural Transm. Suppl 48:1996;29-43.
77. Ann Neurol. 39:1996;37-45.
78. Offen D., Ziv I., Sternin H. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of parkinson's disease. Exp Neurol. 141:1996;32-39.
79. Riederer P., Sofic E., Rausch W.-D. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J Neurochem. 52:1989;515-520.